

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Monday, September 11, 2017 12:47 PM  
**To:** Rizwana Sproule (RSproule@KitePharma.com)  
**Cc:** 'Alex Babayan'; 'Nadia Agopyan'  
**Subject:** Kite Pharma 125643 Clinical IR 9.11.17

Dear Dr. Sproule,

Please provide the following information from ZUMA-1 and ZUMA-2 (the 10 subjects who were treated with KTE-C19 CLP process) in dataset and table format:

- Incidence of subsequent rehospitalizations after initial discharge (please provide median duration/min/max days of each rehospitalization)
- Relative study start day and end day of rehospitalizations
- Events leading to each subsequent rehospitalization (AEs vs. ICU admission vs. retreatment with KTE-C19)

**Please respond ASAP!**

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."